Blood:EMT调控因子SNAI1通过与LSD1相互作用促进AML进展

2020-05-16 QQY MedSci原创

KDM1A/LSD1是AML的新治疗靶点。SNAI1是AML中KDM1A/LSD1靶向选择的病理调节性因子。 靶向SNAI1-LSD1复合物或其下游靶点,可能是AML的一种新颖而有效的治疗策略。

近年来,上皮-间充质转化(EMT)的调控因子已成为白血病生物学领域的新成员。但EMT调控因子参与白血病发病的机制尚未完全明确。

在本研究中,Carmichael等人发现,EMT的一个关键调控因子,SNAI1的过表达在人急性髓系白血病(AML)中是一种病理相关事件,可导致未成熟髓系细胞分化受损、自我更新和增殖增强。

此外,研究人员还在小鼠中证明了,Snai1在造血细胞中的异位表达可导致急性髓系白血病的发生。这种作用是通过与组蛋白去甲基酶KDM1A/LSD1的相互作用介导的。

本研究揭示了SNAI1在白血病发展中的新作用,并确定了LSD1在癌症中破坏的新机制。鉴于目前人们对LSD1抑制剂在治疗包括AML在内的多种不同恶性肿瘤的兴趣,这一点尤其重要。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909298, encodeId=3668190929805, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Feb 15 08:21:21 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794195, encodeId=147b1e94195e1, content=<a href='/topic/show?id=4e41164e3b9' target=_blank style='color:#2F92EE;'>#SNAI1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16473, encryptionId=4e41164e3b9, topicName=SNAI1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Sat Apr 24 18:21:21 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442758, encodeId=7c021442e58d3, content=<a href='/topic/show?id=df5b1106429' target=_blank style='color:#2F92EE;'>#LSD1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11064, encryptionId=df5b1106429, topicName=LSD1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99ed4977335, createdName=ms1692810954239974, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462135, encodeId=535614621353c, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471660, encodeId=afda14e16609d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909298, encodeId=3668190929805, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Feb 15 08:21:21 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794195, encodeId=147b1e94195e1, content=<a href='/topic/show?id=4e41164e3b9' target=_blank style='color:#2F92EE;'>#SNAI1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16473, encryptionId=4e41164e3b9, topicName=SNAI1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Sat Apr 24 18:21:21 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442758, encodeId=7c021442e58d3, content=<a href='/topic/show?id=df5b1106429' target=_blank style='color:#2F92EE;'>#LSD1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11064, encryptionId=df5b1106429, topicName=LSD1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99ed4977335, createdName=ms1692810954239974, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462135, encodeId=535614621353c, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471660, encodeId=afda14e16609d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2021-04-24 jiangjun073
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909298, encodeId=3668190929805, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Feb 15 08:21:21 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794195, encodeId=147b1e94195e1, content=<a href='/topic/show?id=4e41164e3b9' target=_blank style='color:#2F92EE;'>#SNAI1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16473, encryptionId=4e41164e3b9, topicName=SNAI1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Sat Apr 24 18:21:21 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442758, encodeId=7c021442e58d3, content=<a href='/topic/show?id=df5b1106429' target=_blank style='color:#2F92EE;'>#LSD1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11064, encryptionId=df5b1106429, topicName=LSD1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99ed4977335, createdName=ms1692810954239974, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462135, encodeId=535614621353c, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471660, encodeId=afda14e16609d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1909298, encodeId=3668190929805, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Feb 15 08:21:21 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794195, encodeId=147b1e94195e1, content=<a href='/topic/show?id=4e41164e3b9' target=_blank style='color:#2F92EE;'>#SNAI1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16473, encryptionId=4e41164e3b9, topicName=SNAI1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Sat Apr 24 18:21:21 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442758, encodeId=7c021442e58d3, content=<a href='/topic/show?id=df5b1106429' target=_blank style='color:#2F92EE;'>#LSD1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11064, encryptionId=df5b1106429, topicName=LSD1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99ed4977335, createdName=ms1692810954239974, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462135, encodeId=535614621353c, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471660, encodeId=afda14e16609d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2020-05-18 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1909298, encodeId=3668190929805, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Feb 15 08:21:21 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794195, encodeId=147b1e94195e1, content=<a href='/topic/show?id=4e41164e3b9' target=_blank style='color:#2F92EE;'>#SNAI1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16473, encryptionId=4e41164e3b9, topicName=SNAI1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Sat Apr 24 18:21:21 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442758, encodeId=7c021442e58d3, content=<a href='/topic/show?id=df5b1106429' target=_blank style='color:#2F92EE;'>#LSD1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11064, encryptionId=df5b1106429, topicName=LSD1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99ed4977335, createdName=ms1692810954239974, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462135, encodeId=535614621353c, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471660, encodeId=afda14e16609d, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon May 18 02:21:21 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2020-05-18 ylz8405

相关资讯

Blood:急性髓细胞性白血病的非典型3q26/MECOM重排堪比inv(3)/ t(3;3)

3q26/MECOM重排型AML的特征:EVI1过表达、超级增强型劫持、MDS1-EVI1缺失和GATA2频发缺陷。 3q26/MECOM重排型AML是一种独特的亚型,需要专门的诊断检测。

Brit J Cancer:SLC2A3介导的维生素C摄取减少会促进白血病的发生发展

维生素C是一种能够参与表观遗传重塑的新型肿瘤代谢抑制剂,并提出其可以作为治疗白血病的潜在治疗策略。维生素C是TET酶(Tet甲基胞嘧啶双加氧酶)的辅因子,其可以调节TET的活性。

Blood:Venetoclax联合LDAC可改善不适合强化化疗的AML患者的临床预后

与单用LDAC相比,Venetoclax联合LDAC提高了老年AML患者的缓解率、输血不依赖性和患者报告的预后。 采用Venetoclax联合LDAC治疗的老年AML患者的中位总体存活期长8.4个月

Blood:短端粒综合征个体的易患肿瘤及预后

中心点:肺外短端粒综合征表型使MDS/AML患者的自然史和克隆造血复杂化。大多数短端粒实体瘤发生于DKC1突变男性;这部分人可能从癌症筛查中获益更多。摘要:短端粒与癌症风险相关,但也有证据表明短端粒具有肿瘤抑制作用。在本研究中,研究人员汇报了携带端粒和其他端粒维持基因胚系突变的个体的癌症预后。在以医院为基础的背景下评估的180个人中,12.8%患有癌症。实体瘤罕见(2.8%);几乎所有癌症患者均为

Blood:AML细胞中的CTCF占用率增多与其异常表达基因相关

CTCF是基因表达的关键调节因子;CTCF通过组织染色质结构发挥作用。目前尚不清楚CTCF结合在 白血病或一般癌症中如何受到干扰。

Blood:CDK6是携带NUP98融合蛋白的急性髓系白血病的一个新的潜在治疗靶点

在AML中,NUP98融合蛋白直接调控白血病相关基因表达。 CDK6表达受NUP融合的直接转录调控,NUP98融合变异型AML对CDK6抑制特别敏感。